Biotech closes on $9M for stem cell, cord blood research

09/14/2007 | American City Business Journals

Aldagen has raised $9 million in funding to use for its research with stem cells derived from bone marrow, blood and umbilical cords. The biotech company currently has three drugs trials under way for improving safety in cord blood transfusions and treating advanced heart failure and blocked extremities.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX